Pyrazolopyrimidine derivatives as inhibitors of nlrp3

A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

• wherein
• L is O or a bond;
• X is N or CR4;
• Y is N or CR5;
• R1 is an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted C6-14 aryl group, or an optionally substituted 4- to 6-membered heterocyclic group with the proviso that when L is a bond, then the 4- to 6-membered heterocyclic group is a 4- to 6-membered non-aromatic heterocyclic group which is linked to the pyrazolopyrimidone ring by a carbon-carbon bond;
• R2 is a hydrogen atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C3-8 cycloalkyl group;
• R3 is a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, or a halogen atom;
• and
• R4, R5, R6, R7 and R8 are each independently a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted C2-6 alkenyl group, a halogen atom, a hydroxy group, an optionally substituted C1-6 alkoxy group, or an optionally substituted 5- or 6-membered heterocyclic group a cyano group, an amino group or a nitro group;
• with the proviso that (1) 2,5-dihydro-6-methyl-5-(1-methylethyl)-2-(3-pyridinyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, (2) 5-ethyl-2,5-dihydro-6-methyl-2-(3-pyridinyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one and (3) 5-ethyl-2,5-dihydro-2-(3-pyridinyl)-6-(trifluoromethyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one are excluded.